Literature DB >> 18644994

Silibinin inhibits cytokine-induced signaling cascades and down-regulates inducible nitric oxide synthase in human lung carcinoma A549 cells.

Manesh Chittezhath1, Gagan Deep, Rana P Singh, Chapla Agarwal, Rajesh Agarwal.   

Abstract

Recently, we reported that silibinin inhibits primary lung tumor growth and progression in mice and down-regulates inducible nitric oxide synthase (iNOS) expression in tumors; however, the mechanisms of silibinin action are largely not understood. Also, the activation of signaling pathways inducing various transcription factors are associated with lung carcinogenesis and their inhibition could be an effective strategy to prevent and/or treat lung cancer. Herein, we used human lung epithelial carcinoma A549 cells to explore the potential mechanisms and observed strong iNOS expression by cytokine mixture (containing 100 units/mL IFN-gamma + 0.5 ng/mL interleukin-1beta + 10 ng/mL tumor necrosis factor-alpha). We also examined the cytokine mixture-activated signaling cascades, which could potentially up-regulate iNOS expression, and then examined the effect of silibinin (50-200 mumol/L) on these signaling cascades. Silibinin treatment inhibited, albeit to different extent, the cytokine mixture-induced activation of signal transducer and activator of transcription 1 (Tyr(701)), signal transducer and activator of transcription 3 (Tyr(705)), activator protein-1 family of transcription factors, and nuclear factor-kappaB. The results for activator protein-1 were correlated with the decreased nuclear levels of phosphorylated c-Jun, c-Jun, JunB, JunD, phosphorylated c-Fos, and c-Fos. Further, silibinin also strongly decreased cytokine mixture-induced phosphorylation of extracellular signal-regulated kinase 1/2 but only marginally affected JNK1/2 phosphorylation. Silibinin treatment also decreased constitutive p38 phosphorylation in the presence or absence of cytokine mixture. Downstream of these pathways, silibinin strongly decreased cytokine mixture-induced expression of hypoxia-inducible factor-1alpha without any considerable effect on Akt activation. Cytokine mixture-induced iNOS expression was completely inhibited by silibinin. Overall, these results suggest that silibinin could target multiple cytokine-induced signaling pathways to down-regulate iNOS expression in lung cancer cells and that could contribute to its overall cancer preventive efficacy against lung tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18644994      PMCID: PMC2587409          DOI: 10.1158/1535-7163.MCT-08-0256

Source DB:  PubMed          Journal:  Mol Cancer Ther        ISSN: 1535-7163            Impact factor:   6.261


  42 in total

Review 1.  Nuclear factor-kappaB activation: a question of life or death.

Authors:  Shishir Shishodia; Bharat B Aggarwal
Journal:  J Biochem Mol Biol       Date:  2002-01-31

Review 2.  [Anti-inflammatory action of PPARs].

Authors:  Hiroshi Fujii
Journal:  Nihon Rinsho       Date:  2005-04

Review 3.  The role of mitogen-activated ERK-kinase inhibitors in lung cancer therapy.

Authors:  Alex A Adjei
Journal:  Clin Lung Cancer       Date:  2005-11       Impact factor: 4.785

4.  Silibinin inhibits cell invasion through inactivation of both PI3K-Akt and MAPK signaling pathways.

Authors:  Pei-Ni Chen; Yih-Shou Hsieh; Hui-Ling Chiou; Shu-Chen Chu
Journal:  Chem Biol Interact       Date:  2005-10-20       Impact factor: 5.192

5.  Oral silibinin inhibits lung tumor growth in athymic nude mice and forms a novel chemocombination with doxorubicin targeting nuclear factor kappaB-mediated inducible chemoresistance.

Authors:  Rana P Singh; G U Mallikarjuna; Girish Sharma; Sivanandhan Dhanalakshmi; Anil K Tyagi; Daniel C F Chan; Chapla Agarwal; Rajesh Agarwal
Journal:  Clin Cancer Res       Date:  2004-12-15       Impact factor: 12.531

6.  Cytokines differentially regulate the synthesis of prostanoid and nitric oxide mediators in tumorigenic versus non-tumorigenic mouse lung epithelial cell lines.

Authors:  Lori D Dwyer-Nield; Mary C Srebernak; Bradley S Barrett; Jinhee Ahn; Pippa Cosper; Amy M Meyer; Lori R Kisley; Alison K Bauer; David C Thompson; Alvin M Malkinson
Journal:  Carcinogenesis       Date:  2005-03-03       Impact factor: 4.944

Review 7.  The role of nuclear factor kappa B in the pathogenesis of pulmonary diseases: implications for therapy.

Authors:  Jeffrey G Wright; John W Christman
Journal:  Am J Respir Med       Date:  2003

8.  Anti-inflammatory effects of mitogen-activated protein kinase kinase inhibitor U0126 in an asthma mouse model.

Authors:  Wei Duan; Jasmine H P Chan; Chui Hong Wong; Bernard P Leung; W S Fred Wong
Journal:  J Immunol       Date:  2004-06-01       Impact factor: 5.422

Review 9.  Targeting HIF-1 for cancer therapy.

Authors:  Gregg L Semenza
Journal:  Nat Rev Cancer       Date:  2003-10       Impact factor: 60.716

10.  Chemopreventive effects of silymarin and silibinin on N-butyl-N-(4-hydroxybutyl) nitrosamine induced urinary bladder carcinogenesis in male ICR mice.

Authors:  Alpna Tyagi; Komal Raina; Rana P Singh; Mallikarjuna Gu; Chapla Agarwal; Gail Harrison; L Michael Glode; Rajesh Agarwal
Journal:  Mol Cancer Ther       Date:  2007-12       Impact factor: 6.261

View more
  27 in total

Review 1.  Silybin and the liver: from basic research to clinical practice.

Authors:  Carmela Loguercio; Davide Festi
Journal:  World J Gastroenterol       Date:  2011-05-14       Impact factor: 5.742

2.  Silibinin and its 2,3-dehydro-derivative inhibit basal cell carcinoma growth via suppression of mitogenic signaling and transcription factors activation.

Authors:  Cynthia Tilley; Gagan Deep; Chapla Agarwal; Michael F Wempe; David Biedermann; Kateřina Valentová; Vladimir Kren; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2014-12-09       Impact factor: 4.784

Review 3.  Molecular mechanisms of silibinin-mediated cancer chemoprevention with major emphasis on prostate cancer.

Authors:  Harold Ting; Gagan Deep; Rajesh Agarwal
Journal:  AAPS J       Date:  2013-04-16       Impact factor: 4.009

4.  Silibinin suppresses spontaneous tumorigenesis in APC min/+ mouse model by modulating beta-catenin pathway.

Authors:  Subapriya Rajamanickam; Manjinder Kaur; Balaiya Velmurugan; Rana P Singh; Rajesh Agarwal
Journal:  Pharm Res       Date:  2009-09-25       Impact factor: 4.200

5.  Silibinin inhibits human nonsmall cell lung cancer cell growth through cell-cycle arrest by modulating expression and function of key cell-cycle regulators.

Authors:  Samiha Mateen; Alpna Tyagi; Chapla Agarwal; Rana P Singh; Rajesh Agarwal
Journal:  Mol Carcinog       Date:  2010-03       Impact factor: 4.784

Review 6.  Targeting tumor microenvironment with silibinin: promise and potential for a translational cancer chemopreventive strategy.

Authors:  Gagan Deep; Rajesh Agarwal
Journal:  Curr Cancer Drug Targets       Date:  2013-06       Impact factor: 3.428

7.  Involvement of Ras and AP-1 in Helicobacter pylori-induced expression of COX-2 and iNOS in gastric epithelial AGS cells.

Authors:  Soon Ok Cho; Joo Weon Lim; Kyung Hwan Kim; Hyeyoung Kim
Journal:  Dig Dis Sci       Date:  2009-06-03       Impact factor: 3.199

8.  Epigenetic modifications and p21-cyclin B1 nexus in anticancer effect of histone deacetylase inhibitors in combination with silibinin on non-small cell lung cancer cells.

Authors:  Samiha Mateen; Komal Raina; Anil K Jain; Chapla Agarwal; Daniel Chan; Rajesh Agarwal
Journal:  Epigenetics       Date:  2012-09-10       Impact factor: 4.528

9.  Beneficial effects of the naturally occurring flavonoid silibinin on the prostate cancer microenvironment: role of monocyte chemotactic protein-1 and immune cell recruitment.

Authors:  Harold Ting; Gagan Deep; Sushil Kumar; Anil K Jain; Chapla Agarwal; Rajesh Agarwal
Journal:  Carcinogenesis       Date:  2016-04-02       Impact factor: 4.944

Review 10.  Chemopreventive and anti-cancer efficacy of silibinin against growth and progression of lung cancer.

Authors:  Samiha Mateen; Komal Raina; Rajesh Agarwal
Journal:  Nutr Cancer       Date:  2013       Impact factor: 2.900

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.